aTYR PHARMA INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
aTYR PHARMA INC (ATYR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $8.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $12.52, a 13.18% decline year-over-year.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $14.42, a 210.78% increase year-over-year.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.64, a 6.18% increase year-over-year.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.37, a 10.63% decline year-over-year.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $9.03, a 56.14% decline from fiscal 2024.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $20.59, a 220.72% increase from fiscal 2023.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $6.42, a 25.26% decline from fiscal 2022.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $8.59, a 61.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.00 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | $12.52 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $9.03 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $42.30 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $31.69 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $14.42 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $20.59 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $6.94 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $4.45 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $4.64 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $6.42 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $6.85 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $6.62 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $4.37 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $8.59 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $12.27 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $18.17 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $4.89 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $22.38 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $22.87 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $25.18 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | $25.47 10-Q · filed 2021-05-14 | |||
| 2020-12-31 | $33.73 10-K · filed 2021-03-24 | |||
| 2020-09-30 | $33.83 10-Q · filed 2020-11-13 | |||
| 2020-06-30 | $69.56 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $111.43 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $58.98 10-K · filed 2020-03-26 | |||
| 2019-09-30 | $66.09 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | $71.85 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $5.38 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | $4.72 10-K · filed 2019-03-26 | |||
| 2018-09-30 | $4.92 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $5.11 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | $6.21 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $7.99 10-K · filed 2018-03-20 | |||
| 2017-09-30 | $6.99 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | $6.44 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $6.98 10-Q · filed 2017-05-11 | |||
| 2016-12-31 | $10.17 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $10.79 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |